250 results
8-K
EX-99.1
26vzzrwwv
14 Nov 22
Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:39pm
DEFA14A
vqwxxahk7di739y ec
30 Sep 22
Additional proxy soliciting materials
4:18pm
8-K
EX-2.1
3ru 1gu9w7zx4trqj6
30 Sep 22
Entry into a Material Definitive Agreement
4:15pm
8-K
1uthxc
30 Sep 22
Entry into a Material Definitive Agreement
4:15pm
DEFA14A
EX-99.2
u34ssyjuy0whzqctp
28 Sep 22
Additional proxy soliciting materials
4:59pm
DEFA14A
EX-99.1
p4iwznwo1m30c9yj
28 Sep 22
Additional proxy soliciting materials
4:59pm
8-K
EX-99.1
jg8erqhb n246whqleie
28 Sep 22
Idera Pharmaceuticals Acquires Aceragen
4:29pm
8-K
EX-99.2
ag5iud0c osu3hk
28 Sep 22
Idera Pharmaceuticals Acquires Aceragen
4:29pm
8-K
EX-99.1
6vxhol1
17 May 22
Idera Pharmaceuticals Shares Positive Results from Investigator- Sponsored Trial in Melanoma Patients at Amsterdam UMC
10:14am